New HPV cancer drug IBRX-042 enters first human safety trial
NCT ID NCT05976828
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called IBRX-042 in 12 people with HPV-related cancers that have come back or worsened. The main goal is to find the safest dose and understand side effects. Participants get three injections, one every three weeks, and are closely monitored. This study does not aim to cure the disease but to gather safety information for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chan Soon-Shiong Institute for Medicine (CSSIFM)
El Segundo, California, 90245, United States
-
Texas Oncology Austin Central
Austin, Texas, 78731, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tailored radiation beams aim to outsmart aggressive throat cancer
- HPV vaccine in healthy donors could help fight cancer
- Can a simple blood test predict cancer return? new study investigates
- Experimental immune therapy aims to tackle HPV cancers before standard care
- Supercharged immune cells take on HPV cancers
- Blood test could guide anal cancer treatment, reducing side effects